Treatment of pediatric non-Hodgkin lymphomas in a country with limited resources: Results of the first national protocol in Nicaragua

Pediatric Blood and Cancer

Volumn 50, Issue 1, 2008, Pages 148-152

  Baez, F ^a   Pillon, M ^b   Manfredini, L ^c   Ocampo, E ^a   Mendez, G ^a   Ortiz, R ^a   Palacios, R ^a   Gutierrez, T ^a   Tridello, G ^b   Conter, V ^d   Valsecchi, M G ^e   Fossati Bellani, F ^f   Cavalli, F ^g   Masera, G ^d   Rosolen, A ^b  

^a Hospital Infantil la Mascota   (Nicaragua)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Child; Developing countries; Non Hodgkin lymphoma; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER RADIOTHERAPY; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; NICARAGUA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SOCIOECONOMICS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; FEMALE; HUMANS; INFANT; LYMPHOMA, NON-HODGKIN; MALE; NICARAGUA;

EID: 36849091851     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21046     Document Type: Article

References (26)

1. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB 89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-3379.
2. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM90. Blood 1999;94:3294-3306.
3. Atra A, Imeson JD, Hobson R, et al. Improved outcome in children with advanced stage B-cell non Hodgkin's lymphoma (B-NHL): Results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 2000;82:1396-1402.
4. Cairo MS, Krailo MD, Morse M, et al. Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: A children's cancer group report. Leukemia 2002;16:594-600.
5. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM Group report. Blood 2000;95:416-421.
6. Brugieres L, Deley MC, Pacquement H, et al. CD 30(+) anaplastic large-cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of French Society of Pediatric Oncology. Blood 1998;92:3591-3598.
7. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994;12:899-908.
8. Masera G, Baez F, Biondi A, et al. North-South twinning in paediatric hemato-oncology: The La Mascota programme, Nicaragua. Lancet 1998;352:1923-1926.
9. Spinetta J, Masera G, Eden T, et al. Refusal, non-compliance, and abandonment of treatment in children and adolescent with cancer: A report of the SIOP Working Committee on Phychosocial Issues in Pediatric Oncology. Med Pediatr Oncol 2002;38:114-117.
10. Brown S, Belgaumi A, Ajarim D, et al. Loss to follow-up of patients with malignant lymphoma. Eur J Cancer Care 2004;13:180-184.
11. Willimas JA, Ribeiro RC. Pediatric haematology-oncology outreach for developing countries. Hematol Oncol Clin North Am 2001;15:775-787.
12. Valsecchi MG, Tognoni G, Bonilla M, et al. Clinical epidemiology of childhood cancer in Central America and Caribbean countries. Ann Oncol 2004;15:680-685.
13. Usmani GN. Paediatric oncology in the third word. Curr Opin Pediatr 2001;13:1-9.
14. Barr RD, Ribeiro RC, Agarwal BR, et al. Pediatric oncology in countries with limited resources. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology, 4th edition., Philadelphia: Lippincott-Raven Publications. 2002; pp 1541-1552.
15. Percy C, O'Conor G, Ries LG, Jaffe ES. Non-Hodgkin's lymphomas. Application of the International Classification of Diseases for Oncology (ICD-O) to the Working Formulation. Cancer 1984;54:1435-1438.
16. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas [erratum appears in Lancet. 1988;13:372]. Lancet 1988;1:292-293.
17. World Health Organization Classification of Tumours. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology & genetics: Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001.
18. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's Lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 1980;7:332-339.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
20. Eden T, Pui CH, Schrappe M, Tognoni G, Masera G. All children have the right to full access to treatment for cancer. Lancet 2004;364:1121-1122.
21. Hesseling PB, Broadhead R, Molyneux E, et al. Malawi pilot study of Burkitt lymphoma treatment. Med Ped Oncol 2003;41:532-540.
22. Meremikwu MM, Ehiri JE, Nkanga DG, et al. Socioeconomic constraints to effective management of Burkitt's lymphoma in South-eastern Nigeria. Trop Med Int Health 2005;10:92-98.
23. Metzger ML, Howard SC, Fu LC, et al. Outcome of childhood acute lymphoblastic leukemia in resource poor countries. Lancet 2003;362:706-708.
24. Curtis E. Child health and international monetary fund: The Nicaragua experience. Lancet 1998;352:1622-1624.
25. Sala A, Barr RD, Masera G. A survey of resources and activities in the MISPHO family of institutions in Latin America: A comparison of two eras. Pediatric Blood Cancer 2004;43:1-7.
26. Masera G, Lanfranco P, Sala A. The Monza's International School of Pediatric Hematology and Oncology (MISPHO) for countries with limited resources: A three years experience. Med Ped Oncol 1998;31:219.